Cue Biopharma to Host Business Update Call and Webcast
Cue Biopharma (Nasdaq: CUE) has announced a conference call and webcast scheduled for August 19, 2024, at 4:30 p.m. EDT to provide a business update. The company will discuss its recent restructuring and strategic prioritization, focusing on enhancing near-term shareholder value by:
- Refocusing resources on autoimmune programs CUE-401 and CUE-501
- Allowing data from ongoing oncology trials for CUE-101 and CUE-102 to mature
The call will also cover clinical and business updates, market opportunities, and anticipated near-term milestones. Investors can access the call via phone or webcast, with options for both domestic and international participants.
Cue Biopharma (Nasdaq: CUE) ha annunciato una conferenza telefonica e una trasmissione in streaming programmate per 19 agosto 2024, alle 16:30 EDT per fornire un aggiornamento aziendale. L'azienda discuterà la sua recente ristrutturazione e le priorità strategiche, concentrandosi sull'aumento del valore per gli azionisti a breve termine mediante:
- Riorientamento delle risorse sui programmi autoimmuni CUE-401 e CUE-501
- Consentire ai dati degli studi oncologici in corso per CUE-101 e CUE-102 di maturare
La chiamata tratterà anche aggiornamenti clinici e aziendali, opportunità di mercato e traguardi attesi a breve termine. Gli investitori possono accedere alla chiamata tramite telefono o streaming, con opzioni per partecipanti sia nazionali che internazionali.
Cue Biopharma (Nasdaq: CUE) ha anunciado una conferencia telefónica y una transmisión web programadas para 19 de agosto de 2024, a las 4:30 p.m. EDT para proporcionar una actualización empresarial. La compañía discutirá su reciente reestructuración y priorización estratégica, centrándose en aumentar el valor para los accionistas a corto plazo mediante:
- Reenfoque de recursos en los programas autoinmunes CUE-401 y CUE-501
- Permitir que los datos de los ensayos oncológicos en curso para CUE-101 y CUE-102 maduren
La llamada también cubrirá actualizaciones clínicas y empresariales, oportunidades de mercado y hitos esperados a corto plazo. Los inversores pueden acceder a la llamada a través de teléfono o transmisión web, con opciones para participantes tanto nacionales como internacionales.
Cue Biopharma (Nasdaq: CUE)는 2024년 8월 19일 오후 4시 30분 EDT에 예정된 전화 회의 및 웹캐스트를 통해 비즈니스 업데이트를 제공한다고 발표했습니다. 회사는 최근의 구조조정 및 전략적 우선순위를 논의하며, 단기적으로 주주 가치를 증대시키는 데 집중합니다:
- 자가면역 프로그램인 CUE-401 및 CUE-501에 자원을 재초점 맞추기
- CUE-101 및 CUE-102의 진행 중인 종양학 시험 데이터가 성숙해지도록 허용하기
이번 전화 회의에서는 임상 및 비즈니스 업데이트, 시장 기회 및 기대되는 단기 마일스톤에 대한 내용도 다룰 예정입니다. 투자자들은 전화나 웹캐스트를 통해 이 회의에 접근할 수 있으며, 국내외 참가자를 위한 옵션이 있습니다.
Cue Biopharma (Nasdaq: CUE) a annoncé une conférence téléphonique et un webinaire prévus pour le 19 août 2024, à 16h30 EDT afin de fournir une mise à jour sur l'entreprise. La société discutera de sa récente restructuration et de ses priorités stratégiques, en mettant l'accent sur l'amélioration de la valeur à court terme pour les actionnaires par :
- Réorientation des ressources vers les programmes auto-immuns CUE-401 et CUE-501
- Permettre aux données des essais oncologiques en cours pour CUE-101 et CUE-102 de mûrir
La conférence abordera également des mises à jour cliniques et commerciales, des opportunités de marché et des jalons attendus à court terme. Les investisseurs peuvent accéder à l'appel par téléphone ou webinaire, avec des options pour les participants nationaux et internationaux.
Cue Biopharma (Nasdaq: CUE) hat eine Telefonkonferenz und einen Webcast angekündigt, die für 19. August 2024, um 16:30 Uhr EDT geplant sind, um ein Unternehmensupdate bereitzustellen. Das Unternehmen wird über seine jüngste Umstrukturierung und strategische Prioritäten diskutieren, mit dem Fokus auf die Steigerung des kurzfristigen Shareholder-Values durch:
- Neuausrichtung der Ressourcen auf die Autoimmun-Programme CUE-401 und CUE-501
- Ermöglichung des Reifens von Daten aus den laufenden Onkologie-Studien zu CUE-101 und CUE-102
Das Gespräch wird auch klinische und geschäftliche Updates, Marktchancen und erwartete kurzfristige Meilensteine ansprechen. Investoren können über Telefon oder Webcast auf die Sitzung zugreifen, mit Optionen für nationale und internationale Teilnehmer.
- None.
- None.
BOSTON, Aug. 13, 2024 (GLOBE NEWSWIRE) -- Cue Biopharma, Inc. (Nasdaq: CUE), a clinical-stage biopharmaceutical company developing a novel class of therapeutic biologics to selectively engage and modulate disease-specific T cells, announced today that it will host a conference call and webcast to provide a business update on Monday, August 19, 2024 at 4:30 p.m. EDT. Live and archived versions of the event can be accessed via the Company’s website.
The company will provide a business overview of its recent restructuring and near-term strategic prioritization objectives. The discussion will focus on the company’s approach to enhance near-term shareholder value by refocusing resources on further development of its ongoing autoimmune programs, CUE-401 and CUE-501, while enabling data from its ongoing oncology trials for CUE-101 and CUE-102 to continue to mature. Additional clinical and business updates, as well as market opportunities and anticipated near-term milestones, will also be addressed.
Webcast Details
Monday, August 19 at 4:30 p.m. EDT
| Investors: | 1-844-826-3035 | |
| International Investors: | 1-412-317-5195 | |
| Conference ID: | 10191414 | |
| Request a return call via the Call me™ link: | https://callme.viavid.com/?$Y2FsbG1lPXRydWUmcGFzc2NvZGU9JmluZm89Y29tcGFueSZyPXRydWUmYj0xNg== | |
| Participants can use guest dial-in numbers above and be answered by an operator OR click the Call me™ link for instant telephone access to the event. The link will be active 15 minutes prior to the scheduled start time. | ||
| Webcast: | https://viavid.webcasts.com/starthere.jsp?ei=1682217&tp_key=cc61641c8f | |
About Cue Biopharma
Cue Biopharma, a clinical-stage biopharmaceutical company, is developing a novel class of injectable biologics to selectively engage and modulate disease-specific T cells directly within the patient’s body. The company’s proprietary platform, Immuno-STAT™ (Selective Targeting and Alteration of T cells) and biologics are designed to harness the curative potential of the body’s intrinsic immune system through the selective modulation of disease-specific T cells without the adverse effects of broad systemic immune modulation.
Headquartered in Boston, Massachusetts, we are led by an experienced management team and independent Board of Directors with deep expertise in immunology and immuno-oncology as well as the design and clinical development of protein biologics.
For more information please visit www.cuebiopharma.com and follow us on X and LinkedIn.
Investor Contact
Marie Campinell
Senior Director, Corporate Communications
Cue Biopharma, Inc.
mcampinell@cuebio.com
Media Contact
Jonathan Pappas
LifeSci Communications
jpappas@lifescicomms.com
FAQ
When is Cue Biopharma's business update call scheduled for?
What will be the main focus of Cue Biopharma's business update?
Which ongoing clinical trials will Cue Biopharma discuss during the call?
How can investors access Cue Biopharma's business update call on August 19, 2024?
